Status:
UNKNOWN
Plasma Rich in Growth Factors for Treatment of Medication Related Osteonecrosis of the Jaw
Lead Sponsor:
University of Roma La Sapienza
Collaborating Sponsors:
NYU College of Dentistry
Universidade da Coruña
Conditions:
Osteonecrosis Due to Drugs, Jaw
Eligibility:
All Genders
Phase:
PHASE2
PHASE3
Brief Summary
Medication related Osteonecrosis of the Jaw (MRONJ) consists of progressive destruction of bone in the maxillofacial area. It is an established complication which occurs in patients who take two main ...
Eligibility Criteria
Inclusion
- Subjects must be candidates for surgical treatment for MRONJ at stage 2 or 3.
- Subjects must be \>18 and \<80 years of age
- Subjects must sign a informed consent prior to randomization and must agree to return to scheduled follow-up visits
Exclusion
- Subject has inability to understand and cooperate with the study procedures or provide informed consent
- Subject has bleeding diathesis or coaugolapthy, or will refuse autologous blood sampling
- Subject had a cardiovascular event in the past 30 days
- Subject has any condition that limits their anticipated survival to less than 3 months
Key Trial Info
Start Date :
September 1 2018
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 1 2022
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT03390777
Start Date
September 1 2018
End Date
January 1 2022
Last Update
January 8 2018
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.